Generic Name and Formulations:
Icatibant 10mg/mL; soln for SC inj; preservative-free.
Shire US, Inc.
Indications for FIRAZYR:
Treatment of acute attacks of hereditary angioedema (HAE).
≥18yrs: 30mg SC in abdominal area; may give additional doses at intervals of at least 6 hours if response inadequate or symptoms recur. Max 3 doses/24hrs.
<18yrs: not recommended.
Advise patients to seek medical attention after treating laryngeal attack given the potential for airway obstruction. Elderly. Labor & delivery. Pregnancy (Cat.C). Nursing mothers.
Bradykinin B2 receptor antagonist.
May attenuate the antihypertensive effect of ACE inhibitors.
Inj site reactions, pyrexia, transaminase increase, dizziness, rash.
Single-use prefilled syringe (3mL)—1, 3
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Differences in Efficacy and Tolerability of ADHD Medications Across Age Groups
- Associations Between Hypovitaminosis D and Poorer Outcomes in Schizophrenia
- Oxycontin's Maker Now Selling Drug to Curb Opioid Addiction
- Comorbid Narcolepsy and Schizophrenia in Adolescents
- FDA Approves New Treatment for Opioid Dependence
- Gestational Diabetes Associated With Increased Risk for Postpartum Depression
- Combination Cognitive Behavioral Therapy With Fluoxetine Effective for Adolescent Depression
- Smartphone-Based Psychoeducational Programs May Be Effective for Bipolar Disorder Management
- Prazosin May Be Effective as Treatment for Alcohol Use Disorder
- Risk Factors for Recurrent Suicide Attempts in Substance Use Disorder Outpatients